Repligen posts record Q3 revenue, beats earnings and lifts FY2026 guidance after BioLife acquisition
Repligen Corporation reported third‑quarter 2026 revenue of $209.3 million, up 11% year‑over‑year and 12.5% on an organic basis. Adjusted earnings were $0.53 per share, while GAAP results showed a loss of $0.68 per share after a $41.2 million impairment. The company completed its BioLife Solutions acquisition and raised full‑year 2026 revenue guidance to $844 million‑$852 million, with adjusted EPS guidance of $2.05‑$2.09 per share.
Why it matters
The higher revenue and EPS guidance signals stronger growth prospects for FY2026, which may support the stock’s valuation (the company’s own guidance and analysts’ expectations). However, the pre‑market share dip of about 2.3% reflects investor concern over near‑term margin pressure and the $41 million charge.
Key facts
- 1Q3 2026 reported revenue was $209.3 million, an 11% increase year‑over‑year and 12.5% organic growth. stocktitan.net
- 2Adjusted EPS for the quarter was $0.53 per share. stocktitan.net
- 3GAAP loss per share was $0.68, driven by a $41.2 million intangible‑asset impairment. 247wallst.com
- 4Full‑year 2026 revenue guidance was raised to a range of $844 million‑$852 million. stocktitan.net
- 5Adjusted FY2026 EPS guidance was set at $2.05‑$2.09 per share. finance.yahoo.com
- 6The BioLife Solutions acquisition closed in early October 2026. stocktitan.net
Summary written by AlphAI AI Desk from 13 of 13 sources. Not investment advice. Figures are as stated by the linked sources.